How to Get AndroGel in New Jersey

Who Can Prescribe AndroGel in New Jersey

Any physician (MD or DO) licensed by the New Jersey State Board of Medical Examiners can prescribe AndroGel. The prescriber does not need to be an endocrinologist. Primary care physicians, urologists, and men's health specialists all write testosterone prescriptions routinely across the state.

Nurse practitioners in New Jersey gained full practice authority under the NJ Advanced Practice Nurse Modernization Act, though prescribing Schedule III controlled substances like testosterone still requires a collaborative agreement with a licensed physician during the first 24 months of practice. Physician assistants may prescribe AndroGel under their supervising physician's delegated authority.

Because testosterone gel is a Schedule III controlled substance under federal law and New Jersey's Controlled Dangerous Substances Act (N.J.S.A. 24:21-1), the prescriber must hold both a valid DEA registration and a New Jersey CDS registration. Prescriptions must be transmitted electronically under New Jersey's EPCS mandate. Paper prescriptions are accepted only when the electronic system is temporarily unavailable, and the prescriber documents the reason for the exception.

Telehealth Prescribing Rules in New Jersey

New Jersey permits telehealth prescribing of AndroGel. That is a straightforward fact. The state's telehealth parity law (P.L. 2017, c.117) requires insurers to cover telehealth visits at the same rate as in-person appointments, and no separate in-person visit is mandated before a provider can prescribe a controlled substance via telemedicine in New Jersey.

A telehealth provider must hold an active New Jersey medical license or be registered through the Interstate Medical Licensure Compact. The provider must verify the patient's New Jersey location at the time of the visit. The Testosterone Trials, a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, confirmed that testosterone gel produced statistically significant improvements in sexual function, physical activity, and mood over 12 months 1. These findings inform the clinical rationale that telehealth providers use when evaluating candidates for testosterone replacement.

HealthRX and similar telehealth platforms operating in New Jersey typically follow a streamlined workflow: the patient completes a medical intake, the platform orders labs at a local draw site, a licensed clinician reviews results by video or asynchronous visit, and the prescription routes to a pharmacy electronically. Most patients receive their medication within 3 to 7 business days of the clinical visit.

Lab Work Required Before a Prescription

The Endocrine Society's 2018 Clinical Practice Guideline requires two separate morning fasting total testosterone measurements below 300 ng/dL before diagnosing male hypogonadism. Morning draws matter. Testosterone follows a circadian rhythm, peaking between 7:00 and 10:00 AM, with levels dropping 20 to 25% by late afternoon.

A standard pre-treatment lab panel for New Jersey patients includes:

• Total testosterone (two draws, morning fasting)
• Free testosterone or bioavailable testosterone
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
• Complete blood count with hematocrit
• Comprehensive metabolic panel
• Lipid panel
• Prostate-specific antigen (PSA) for men over 40
• Estradiol (sensitive assay)

Hematocrit deserves particular attention. The FDA's prescribing information for AndroGel warns that testosterone can increase red blood cell mass, raising the risk of polycythemia. If baseline hematocrit exceeds 50%, most clinicians will defer treatment until the cause is identified. During treatment, the Endocrine Society recommends monitoring hematocrit at 3 to 6 months and then annually, with dose reduction or temporary discontinuation if hematocrit exceeds 54% 2.

Dr. Shalender Bhasin, the principal investigator of the Testosterone Trials and professor at Brigham and Women's Hospital, stated: "The diagnosis of hypogonadism requires unequivocally low testosterone on at least two occasions, measured by a reliable assay, in the setting of consistent signs and symptoms" 1.

Quest Diagnostics and Labcorp both operate over 100 patient service centers across New Jersey, from Bergen County to Cape May. Walk-in draws are available at most locations with a lab order.

AndroGel Dosing and How to Use It

AndroGel 1% comes in metered-dose pumps and single-use packets. The standard starting dose is 50 mg of testosterone (four pump actuations of the 1% formulation or one 5 g packet) applied once daily to clean, dry skin on the shoulders, upper arms, or abdomen. Do not apply it to the chest or genitals.

Key application rules from the FDA label:

• Apply at the same time each morning
• Allow the gel to dry completely before dressing (typically 5 to 10 minutes)
• Wash hands thoroughly with soap and water after application
• Cover the application site with clothing once dry
• Avoid skin-to-skin contact with women and children at the application site for at least 2 hours

The risk of secondary transfer is real. The FDA label carries a boxed warning about virilization in children following secondary exposure through skin contact. The Endocrine Society guideline reinforces that patients should be counseled on transfer precautions at every visit 2.

Dose adjustments happen at the 2 to 4 week mark based on a serum testosterone trough level drawn before the morning application. The target range is typically 400 to 700 ng/dL. The maximum FDA-approved dose is 100 mg daily for AndroGel 1%.

Insurance and Prior Authorization in New Jersey

AndroGel carries a wholesale acquisition cost of approximately $650 to $800 for a 30-day supply of the brand-name 1% pump. Generic testosterone gel 1% ranges from $80 to $200 depending on the pharmacy and payer.

New Jersey Medicaid covers AndroGel for male hypogonadism with prior authorization. The PA process typically requires:

• Two documented morning testosterone levels below 300 ng/dL
• ICD-10 diagnosis code E29.1 (testicular hypofunction)
• Documentation that the patient has signs or symptoms consistent with hypogonadism
• Confirmation that the prescriber considered generic testosterone gel before brand-name AndroGel

Commercial insurers in New Jersey, including Horizon Blue Cross Blue Shield, Aetna, and UnitedHealthcare, generally require step therapy. This means trying generic testosterone gel 1% before the plan will cover brand-name AndroGel. A formulary exception request can bypass step therapy when the prescriber documents clinical justification (for example, an adverse reaction to the generic formulation or a pharmacokinetic reason to prefer the brand).

The American Urological Association's 2018 guideline on testosterone deficiency notes that "treatment decisions should be individualized based on patient symptoms, testosterone levels, comorbidities, and shared decision-making" 3. This language supports formulary exception requests when a specific formulation is medically necessary.

Appeals in New Jersey must follow the timeline set by N.J.A.C. 11:24A. Insurers must respond to standard PA requests within 5 business days and urgent requests within 24 hours.

503A Compounding Pharmacies in New Jersey

New Jersey licenses 503A compounding pharmacies under the New Jersey Board of Pharmacy (N.J.A.C. 13:39). These pharmacies can compound testosterone gel in custom concentrations (often 5%, 10%, or 20%) based on a patient-specific prescription. They cannot manufacture in bulk without prescriptions on file.

Compounded testosterone gel is not FDA-approved, but it is legal when dispensed against a valid prescription. Compounded formulations typically cost $30 to $80 per month, making them substantially less expensive than brand-name AndroGel. The tradeoff is variability. The FDA has noted that compounded drugs do not undergo the same rigorous testing for potency, purity, and bioavailability as FDA-approved products 4.

Several accredited compounding pharmacies operate in New Jersey, including facilities in Morris County, Middlesex County, and Burlington County. Accreditation through the Pharmacy Compounding Accreditation Board (PCAB) or similar bodies provides an additional quality signal, though it is voluntary. Patients should ask whether the pharmacy performs third-party potency testing on finished preparations.

503A pharmacies in New Jersey can ship compounded testosterone gel directly to patients within the state. Interstate shipping from a 503A pharmacy requires that the pharmacy also hold a license in the receiving state.

Transferring a Prescription to New Jersey

If you already have a testosterone gel prescription from another state, a New Jersey pharmacist can accept a prescription transfer for Schedule III substances. The process follows federal regulations under 21 CFR 1306.26.

The transferring pharmacist must communicate directly with the receiving pharmacy (by phone or electronically). The original prescription is voided at the sending pharmacy. Remaining refills transfer to the new pharmacy. Only one transfer is permitted for Schedule III through V drugs unless both pharmacies share a real-time online database.

Alternatively, if you are switching to a New Jersey-based telehealth provider, they will likely issue a new prescription rather than transfer the old one. This avoids transfer limitations and allows the new prescriber to establish a clinical relationship and verify recent lab work.

Monitoring After Starting AndroGel

Treatment does not end at the prescription. The Endocrine Society recommends follow-up labs at 3 months, 6 months, and then every 6 to 12 months 2. The monitoring panel typically includes:

• Total testosterone (trough, before morning application)
• Hematocrit and hemoglobin
• PSA (in men over 40)
• Estradiol
• Liver function tests (if clinically indicated)

In the Testosterone Trials, men receiving testosterone gel showed mean serum testosterone increases from approximately 232 ng/dL to 470 ng/dL at 12 months, with consistent improvements across the sexual function, physical function, and vitality domains 1. These results were achieved with careful dose titration and monitoring, reinforcing that follow-up is not optional.

The American Urological Association's guideline specifically recommends evaluating patients for sleep apnea symptoms at follow-up visits, as testosterone therapy may worsen obstructive sleep apnea in susceptible individuals 3. New or worsening snoring, daytime somnolence, or witnessed apneas should prompt a formal sleep study.

Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School and past president of the Androgen Society, has written: "Monitoring is the clinical safeguard that separates responsible testosterone therapy from unsupervised hormone use" 3.

Timeline: From First Visit to First Application

Here is a realistic timeline for a New Jersey patient starting AndroGel through telehealth:

Day 1 to 3: Complete online intake, medical history questionnaire, and schedule lab work at a local draw site.

Day 3 to 5: Lab draw at Quest, Labcorp, or a partner phlebotomy site. Results typically return within 24 to 48 hours.

Day 5 to 8: Clinician reviews labs, conducts a video or asynchronous visit, and issues the electronic prescription if criteria are met.

Day 8 to 12: Pharmacy fills and ships the medication. Retail pharmacies can fill same-day with electronic prescriptions; mail-order compounding pharmacies ship within 2 to 5 business days.

Total elapsed time: roughly 8 to 14 days from intake to first application. Patients with recent lab work (within 6 months) who meet diagnostic criteria may move faster if their new provider accepts outside labs.